Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Mitiglinide Calcium raw material Powder
Product Overview:
Glinide hypoglycemic agents have the characteristics of rapid, strong and short-term effect, avoiding the occurrence of adverse reactions such as hypoglycemia, and there is no adverse reactions of α-glycosidase inhibitors in the gastrointestinal tract, so it is a more competitive postpranational blood glucose regulator. Miglinide can stimulate the pancreas to secrete insulin quickly and briefly only when eating, and the effect is fast and the effect lasts for a short time. Traditional oral diabetes drugs continue to stimulate insulin secretion, and excessive stimulation, especially between meals, often make patients feel hungry, and even encourage patients to take snacks between meals when using sulfonyl pulse drugs, so that excessive insulin metabolism. This extra eating causes patients to gain weight, and they are often obese to begin with.
Mitiglinide Calcium raw material Powder Attributes
CAS:145525-41-3
MF:(C19H24NO3)2.Ca
MW:668.88
EINECS:692-046-9
Specification: 99% min Mitiglinide Calcium Powder
Sample:Mitiglinide Calcium Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Mitiglinide Calcium raw material Powder Details
Mitiglinide Calcium powder Usage and Synthesis.
Miglinide can close K+-ATP channels on islet beta cells, increase intracellular Ca2+ concentration, and degranulate extracellular insulin-containing vesicles, thus stimulating insulin secretion. In vitro experiments show that calcium miglinide can stimulate the secretion of insulin from isolated hamster islet cells. Electrophysiological studies have shown that this product can inhibit the opening degree of ATP-sensitive K+ channel, and at the concentration of 10μmol/L, this channel can be completely blocked and Ca2+ can be stimulated to enter cells. In the presence of glucose, calcium miglinide can dose-dependently stimulate insulin secretion from rat isolated and isolated perfused pancreas.
Uses of Mitiglinide Calcium.
Both miglinide and nateglinide are fast-acting insulin secreting agents, but miglinide shows a more significant improvement in postpranational hyperglycemia. The effect of miglinide on insulin secretion in HIT-T15 cells is about 100 times greater than that of nateglinide, and the effect on insulin secretion in type 2 diabetic animals is more significant than that of nateglinide. Clinical trials have shown that this class of drugs is superior to other hypoglycemic drugs so far in terms of efficacy and safety, and is a new type of fast-acting "meal blood glucose regulator" that promotes insulin secretion by islet cells. It is suitable for type 2 diabetes patients who cannot effectively control hyperglycemia through diet and exercise therapy, mainly for controlling postprandial hyperglycemia.
Drug combination of Mitiglinide Calcium.
Product Methods of Mitiglinide Calcium.
